The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis

Neuropsychopharmacology

Volumn 29, Issue 8, 2004, Pages 1558-1572

  D'Souza, Deepak Cyril ^a,b,c   Perry, Edward ^a,c   MacDougall, Lisa ^a,c   Ammerman, Yola ^a,c   Cooper, Thomas ^e,f   Wu, Yu Te ^b,d   Braley, Gabriel ^a,c   Gueorguieva, Ralitza ^b,d   Krystal, John Harrison ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY   (United States)

^e Columbia University ^*  (United States)

^f NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Cannabinoids; Cannabis; Cognition; Delta 9 tetrahydrocannabinol; Psychosis; Schizophrenia

Indexed keywords

CANNABIS; DRONABINOL; HYDROCORTISONE;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; CANNABIS ADDICTION; COGNITION; CONTROLLED STUDY; DISTRACTIBILITY; ENDOCRINE FUNCTION; EUPHORIA; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; ORIENTATION; PERCEPTION; PRIORITY JOURNAL; PSYCHOSIS; SAFETY; SCHIZOPHRENIA; SYMPTOM; TASK PERFORMANCE; WORD RECOGNITION; WORKING MEMORY;

ADULT; ANXIETY; AROUSAL; ATTENTION; BEHAVIOR; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HEMODYNAMIC PROCESSES; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; MEMORY, SHORT-TERM; MENTAL RECALL; PANIC; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; SPEECH; TETRAHYDROCANNABINOL; VERBAL LEARNING;

EID: 3242789385     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300496     Document Type: Article

References (148)

1. Acquas E, Pisanu A, Marrocu P, Di Chiara G (2000). Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 401: 179-185.
2. Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G (2001). Delta9-tetrahydrocannabinol enhances cortical hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 419: 155-161.
3. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998). Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43: 811-816.
4. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H et al (1986). Pharmacokinetics metabolism of delta 1-tetrahydrocannabinol other cannabinoids with emphasis on man. Pharmacol Rev 38: 21-43.
5. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987). Cannabis schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483-1486.
6. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1988). Cannabis schizophrenia. Lancet 1: 1000-1001.
7. Andreasson S, Allebeck P, Rydberg U (1989). Schizophrenia in users nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand 79: 505-510.
8. Angrist B, Sathananthan G, Wilk S, Gershon S (1974). Amphetamine psychosis: behavioral biochemical aspects. J Psychiatr Res 11: 13-23.
9. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence risk for adult psychosis: longitudinal prospective study. BMJ 325: 1212-1213.
10. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83: 3287-3293.
11. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992). Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content number of puffs. J Pharmacol Exp Ther 261: 114-122.
12. Belger A, Puce A, Krystal JH, Gore JC, Goldman-Rakic P, McCarthy G (1998). Dissociation of mnemonic perceptual processes during spatial nonspatial working memory using fMRI. Hum Brain Mapping 6: 14-32.
13. Belmore SM, Miller LL (1980). Levels of processing acute effects of marijuana on memory. Pharmacol Biochem Behav 13: 199-203.
14. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal aging rats. Neurotoxicol Teratol 17: 25-30.
15. Beringer KVBW, Marx H (1932). des Haschischrausches (Clinical study on effects of hashish). Der Nervenarzt Berlin 337-350.
16. Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A (2000). Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 95: 5-7.
17. Borkowski JG, Benton AL, Spreen O (1967). Word fluency and brain damage. Neuropsychologia 5: 135-140.
18. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (1995). Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23: 825-831.
19. Brandt J, Corwin J, Krafft L (1992). Is verbal recognition memory really different in Huntington's Alzheimer's disease. J Clin Exp Neuropsychol 14: 773-784.
20. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Traumat Stress 11: 125-136.
21. Brunner E, Domhof S, Langer F (2002). Nonparametric Analysis of Longitudinal Data in Factorial Experiments. John Wiley and Sons: New York, NY.
22. Bylsma FW, Rebok GW, Brandt J (1991). Long-term retention of implicit learning in Huntington's disease. Neuropsychologia 29: 1213-1221.
23. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001). Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol cross-sensitization with morphine. Psychopharmacology 158: 259-266.
24. Carta G, Nava F, Gessa GL (1998). Inhibition of hippocampal acetylcholine release after acute repeated Delta9-tetrahydrocannabinol in rats. Brain Res 809: 1-4.
25. Chait LD, Zacny JP (1992). Reinforcing subjective effects of oral delta 9-THC smoked marijuana in humans. Psychopharmacology 107: 255-262.
26. Chen J, Paredes W, Lowinson JH, Gardner EL (1990a). Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190: 259-262.
27. Chen JP, Parades W, Li J, Smith D, Lowinson J, Gardner EL (1990b). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102: 156-162.
28. Chen JP, Paredes W, Lowinson JH, Gardner EL (1991). Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129: 136-180.
29. Cocchetto DM, Owens SM, Perez-Reyes M, DiGuiseppi S, Miller LL (1981). Relationship between plasma delta-9-tetrahydrocannabinol concentration pharmacologic effects in man. Psychopharmacology 75: 158-164.
30. Collins DR, Pertwee RG, Davies SN (1994). The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. Eur J Pharmacol 259: R7-R8.
31. Collins DR, Pertwee RG, Davies SN (1995). Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 115: 869-870.
32. Compton DR, Johnson MR, Melvin LS, Martin BR (1992). Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260: 201-209.
33. Cone EJ, Huestis MA (1993). Relating blood concentrations of tetrahydrocannabinol metabolites to pharmacologic effects time of marijuana usage. Ther Drug Monit 15: 527-532.
34. Corkin S, Milner B, Rasmussen T (1964). Effects of different cortical excisions on sensory thresholds in man. Trans Am Neurol Assoc 89: 112-116.
35. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002). Cognitive subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164: 61-70.
36. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103: 9-15.
37. Diana M, Melis M, Gessa GL (1998). Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10: 2825-2830.
38. Duncan GE, Sheitman BB, Lieberman JA (1999). An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29: 250-264.
39. Egertova M, Elphick MR (2000). Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422: 159-171.
40. Egertova M, Giang DK, Cravatt BF, Elphick MR (1998). A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase the CB1 receptor in rat brain. Proc Roy Soc London B Biol Sci 265: 2081-2085.
41. Ellison G (1994). Stimulant-induced psychosis, the dopamine theory of schizophrenia, the habenula. Brain Res Brain Res Rev 19: 223-239.
42. Elphick MR, Egertova M (2001). The neurobiology evolution of cannabinoid signaling. Philos Trans Roy Soc London, Ser B 356: 381-408.
43. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan III BF (2000). Potency trends of delta9-THC other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45: 24-30.
44. Emrich HM, Leweke FM, Schneider U (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56: 803-807.
45. Fant RV, Heishman SJ, Bunker EB, Pickworth WB (1998). Acute residual effects of marijuana in humans. Pharmacol Biochem Behav 60: 777-784.
46. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum substantia nigra. Neuroreport 8: 649-652.
47. French ED (1997). delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226: 159-162.
48. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
49. Gerard CM, Mollereau C, Vassart G, Parmentier M (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-134.
50. Gessa GL, Casu MA, Carta G, SMascia M (1998). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex hippocampus reversal by SR 141716A. Eur J Pharmacol 355: 119-124.
51. Gessa GL, Mascia MS, Casu MA, Carta G (1997). Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur J Pharmacol 327: R1-R2.
52. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical quantitative autoradiographic study in the fetal, neonatal adult human brain. Neuroscience 77: 299-318.
53. Gold MS (1991). Marijuana In: Miller eNS (ed). Comprehensive Handbook of Alcohol Drug Addiction. Marcel Decker: New York. pp 353-376.
54. Gordon M (1986). Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull 22: 288-290.
55. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365: 133-142.
56. Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25: 161-164.
57. Haertzen CA (1965). Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 141: 300-307.
58. Haertzen CA (1966). Development of scales based on patterns of drug effects using the addiction Research Center Inventory (ARCI). Psychol Rep 18: 163-194.
59. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000). Cannabinoids inhibit hippocampal GABAergic transmission network oscillations. Eur J Neurosci 12: 3239-3249.
60. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25: 757-765.
61. Heishman SJ, Arasteh K, Stitzer ML (1997). Comparative effects of alcohol marijuana on mood, memory, and performance. Pharmacol Biochem Behav 58: 93-101.
62. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ (1990). Acute residual effects of marijuana: profiles of plasma THC levels, physiological subjective, and performance measures. Pharmacol Biochem Behav 37: 561-565.
63. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991. Characterization localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
64. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
65. Hoffman AF, Lupica CR (2000). Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479.
66. Hollister LE (1988. Cannabis - 1988. Acta Psychiatr Scand Suppl 345: 108-118.
67. Hooker WD, Jones RT (1987). Increased susceptibility to memory intrusions the Stroop interference effect during acute marijuana intoxication. Psychopharmacology 91: 20-24.
68. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
69. Huestis MA, Henningfield JE, Cone EJ (1992). Blood cannabinoids. I. Absorption of THC formation of 11-OH-THC THCCOOH during after smoking marijuana. J Anal Toxicol 16: 276-282.
70. Hunt CA, Jones RT (1980). Tolerance disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215: 35-44.
71. Jentsch JD, Andrusiak E, Tran A, Bowers Jr MB, Roth RH (1997). Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16: 426-432.
72. Johansson E, Noren K, Sjovall J, Halldin MM (1989). Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3: 35-38.
73. Johns A (2001). Psychiatric effects of cannabis. Br J Psychiatry 178: 116-122.
74. Jones RT (1971). Marihuana-induced 'high': influence of expectation, setting and previous drug experience. Pharmacol Rev 23: 359-369.
75. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999a). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
76. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999b). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
77. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000). GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797-804.
78. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 59-67.
79. Kelly PJ, Rubino T (1992). Metabolism of tetrahydrocannabinol in frequent infrequent marijuana users. J Anal Toxicol 16: 28-235.
80. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, and in humans. Psychotomimetic perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
81. Lamarque S, Taghzouti K, Simon H (2001). Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41: 118-129.
82. Laruelle M (2000). The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31: 371-384.
83. Lemberger L, Axelrod J, Kopin IJ (1971). Metabolism disposition of delta-9-tetrahydrocannabinol in man. Pharmacol Rev 23: 371-380.
84. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999a). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10: 1665-1669.
85. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000). Different effects of nabilone cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175-181.
86. Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM (1999b). Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural artificial objects in man. Psychopharmacology (Berlin) 142: 230-235.
87. Lichtman AH, Varvel SA, Martin BR (2002). Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66: 269-285.
88. Lieberman JA, Kane JM, Alvir J (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91: 415-433.
89. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H (1981). Clinical effects plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74: 208-212.
90. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
91. Marks DF, MacAvoy MG (1989). Divided attention performance in cannabis users non-users following alcohol cannabis separately in combination. Psychopharmacology 99: 397-401.
92. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor functional expression of the cloned cDNA. Nature 346: 561-564.
93. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15: 277-281.
94. Mechoulam R, Ben-Shabat S (1999). From gan-zi-gun-nu to anandamide 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Product Rep 16: 131-143.
95. Melis M, Gessa GL, Diana M (2000). Different mechanisms for dopaminergic excitation induced by opiates cannabinoids in the rat midbrain. Prog Neuro-Psychopharmacol Biol Psychiatry 24: 993-1006.
96. Miller LL, Branconnier RJ (1983). Cannabis: effects on memory the cholinergic limbic system. Psychol Bull 93: 441-456.
97. Miller LL, McFarland D, Cornett TL, Brightwell D (1977). Marijuana memory impairment: effect on free recall recognition memory. Pharmacol Biochem Behav 7: 99-103.
98. Misner DL, Sullivan JM (1999). Mechanism of cannabinoid effects on long-term potentiation depression in hippocampal CA1 neurons. J Neurosci 19: 6795-6805.
99. Miyamoto A, Yamamoto T, Ohno M, Watanabe S, Tanaka H, Morimoto S et al (1996). Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res 710: 234-240.
100. Miyamoto A, Yamamoto T, Watanabe S (1995). Effect of repeated administration of delta 9-tetrahydrocannabinol on delayed matching-to-sample performance in rats. Neurosci Lett 201: 139-142.
101. Moreau J (1973) In: Peters NGH (ed). Hashish Mental Illness. Raven Press: New York. pp 245.
102. Moreau de Tours J (1973). Sobre el hachisch y la alienacion mental. Actas Luso-Espanolas Neurol Psiquiatr Cienc Afines 1: 477-484.
103. Murphy LL, Munoz RM, Adrian BA, Villanua MA (1998). Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5: 432-446.
104. Muschamp JW, Siviy SM (2002). Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats. Pharmacol Biochem Behav 73: 835-842.
105. Nava F, Carta G, Colombo G, Gessa GL (2001). Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 41: 392-399.
106. Nowicky AV, Teyler TJ, Vardaris RM (1987). The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Res Bull 19: 663-672.
107. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980a). Plasma delta-9 tetrahydrocannabinol concentrations clinical effects after oral intravenous administration smoking. Clin Pharmacol Ther 28: 409-416.
108. Ohlsson A, Widman M, Carlsson S, Ryman T, Strid C (1980b). Plasma brain levels of delta 6-THC seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol 47: 308-317.
109. Patel S, Hillard CJ (2003). Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Res 963: 15-25.
110. Pertwee RG (1999a). Cannabis cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed 6(Suppl 3): 12-15.
111. Pertwee RG (1999b). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664.
112. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: L1-L6.
113. Pistis M, Muntoni AL, Pillolla G, Gessa GL (2002). Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 15: 1795-1802.
114. Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001). Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14: 96-102.
115. Pitts JE, Neal JD, Gough TA (1992). Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J Pharm Pharmacol 44: 947-951.
116. Porcella A, Gessa GL, Pani L (1998). Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity Fos-related antigens in the rat brain. Eur J Neurosci 10: 1743-1751.
117. Rubino T, Vigano D, Massi P, Parolaro D (2001). The psychoactive ingredient of marijuana induces behavioural sensitization. Eur J Neurosci 14: 884-886.
118. Rubino T, Vigano D, Massi P, Parolaro D (2003). Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization. Eur J Neurosci 17: 325-330.
119. Russo EB, McPartland JM (2003). Cannabis is more than simply delta(9)-tetrahydrocannabinol [comment]. Psychopharmacology 165: 431-432 author reply 433-434.
120. Sadler B, Wall ME, Perez-Reyes M (1984). The pharmacokinetics of delta-9-tetrahydrocannabinol in after simultaneous intravenous oral administration In: The Cannabinoids: Chemical Pharmacologic Therapeutic Aspects. Acadamic Press Inc.: Orlando, Fla. pp 227-238.
121. Schneider U, Leweke FM, Mueller-Vahl KR, Emrich HM (1998). Cannabinoid/anandamide system schizophrenia: is there evidence for association? Pharmacopsychiatry 31: 110-113.
122. Shaw LM, Edling-Owens J, Mattes R (1991). Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector electron-capture negative chemical-ionization mass spectrometry. Clin Chem 37: 2062-2068.
123. Siomopoulos V (1975). Amphetamine psychosis: overview a hypothesis. Dis Nerv System 36: 336-339.
124. Snyder SH (1973). Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 130: 61-67.
125. Solowij N (1998). Cannabis Cognitive Functioning. Cambridge University Press: Cambridge.
126. Solowij N, Michie PT, Fox AM (1991). Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40: 683-688.
127. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW (2003). Abnormal neural synchrony in schizophrenia. J Neurosci 23: 7407-7411.
128. Spitzer RL, Davies M, Barkley RA (1990). The DSM-III-R field trial of disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry 29: 690-697.
129. Sullivan JM (1999). Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. J Neurophysiol 82: 1286-1294.
130. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism (comment). Science 276: 2048-2050.
131. Terranova JP, Michaud JC, Le Fur G, Soubrie P (1995). Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol 352: 576-579.
132. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999). Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93: 969-975.
133. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M et al (2002). CNR1 central cannabinoid receptor gene associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7: 515-518.
134. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002). Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156: 319-327.
135. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A et al (1996). Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67: 29-38.
136. Volkow ND, Fowler JS, Wolf AP, Gillespi H (1991). Metabolic studies of drugs of abuse. NIDA Research Monograph 105: 47-53.
137. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902.
138. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000). Effects of (S)-ketamine on striatal dopamine: a (11C) raclopride PET study of a model psychosis in humans. J Psychiatric Res 34: 35-43.
139. Wall ME, Perez-Reyes M (1981). The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21: 178S-189S.
140. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983). Metabolism disposition and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34: 352-363.
141. Wall ME, Brine DR, Perez-Reyes M (1976). Metabolism of cannabinoids in man In: Braude MC, Szara S (eds). Pharmacology of Marihuana Vol 1, pp 536.
142. World Health Organization (WHO) (1997). Programme on substance abuse. Cannabis: a health perspective and research agenda.
143. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296: 678-682.
144. Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE et al. (1999). Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry 4: 512-523.
145. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199.
146. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol (letter). J Clin Psychiatry 56: 485-486.
147. Zuardi AW, Rodrigues JA, Cunha JM (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104: 260-264.
148. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250.